Artemisinin combination therapy for vivax malaria

Area of Science:

• Malariology
• Infectious Diseases
• Global Health

Background:

• Artemisinin-based combination therapies (ACTs) are vital for malaria elimination programs.
• Currently, ACTs are primarily used for Plasmodium falciparum malaria, while Plasmodium vivax malaria is often treated with chloroquine.
• Co-endemic regions face challenges in managing both Plasmodium species.

Purpose of the Study:

• To review evidence comparing separate treatment strategies with a unified ACT-based approach for co-endemic malaria.
• To evaluate the benefits and drawbacks of each treatment strategy.
• To identify the optimal therapeutic approach for Plasmodium falciparum and Plasmodium vivax in co-endemic areas.

Main Methods:

• Literature review of existing evidence on treatment strategies for P. falciparum and P. vivax malaria.
• Analysis of diagnostic accuracy and drug resistance patterns.
• Comparative assessment of separate versus unified treatment approaches.

Main Results:

• A separate treatment approach is viable if P. vivax remains sensitive to chloroquine and diagnostics are accurate.
• High rates of misdiagnosis and increasing chloroquine resistance in P. vivax challenge the separate approach.
• A unified ACT-based strategy presents a compelling alternative for co-endemic regions.

Conclusions:

• The rise of chloroquine-resistant P. vivax and diagnostic inaccuracies necessitate re-evaluation of malaria treatment protocols.
• A unified ACT-based strategy for both P. falciparum and P. vivax malaria warrants consideration in co-endemic areas.
• Further cost-effectiveness analyses of ACTs for P. vivax are needed to guide control and elimination efforts.